● Recruiting

Study of the CDK4/6 Inhibitor Abemaciclib in Solid Tumors Harboring Genetic Alterations in Genes Encoding D-Type Cyclins or Amplification of CDK4 or CDK6

Condition: Cancer · Sponsor: Dana-Farber Cancer Institute

PhasePhase 2

Planned participants38

Who can joinAll sexes, 18 Years to no upper limit

Healthy volunteersNo

About this study

This research study is studying a targeted therapy as a possible treatment for cancer abnormality in one of the following genes: CCND1, CCND2, CCND3, CDK4, or CDK6. The drug involved in this study is: -Abemaciclib

This description comes directly from the study's public registry record.

Talk to the study team

Geoffrey Shapiro, MD, PhD · 617-632-4942 · geoffrey_shapiro@dfci.harvard.edu

Always discuss trial participation with your own doctor first.

Locations (1)

Dana Farber Cancer Institute

Boston, Massachusetts, United States

Recruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT03310879